Genomic and Biomarker-Based Risk Stratification in AFib Patients
Precision medicine is gaining momentum in atrial fibrillation (AFib) care, with genomic and biomarker-based tools enabling more accurate risk stratification and personalized treatment planning. As innovation accelerates within the Atrial Fibrillation Systems Market, genetic and molecular profiling are proving essential in predicting disease progression, stroke risk, and therapeutic responses.
Single nucleotide polymorphisms (SNPs) in genes like PITX2 and ZFHX3 have been associated with increased susceptibility to AFib, especially in younger individuals without structural heart disease. Additionally, elevated levels of biomarkers such as NT-proBNP, troponin, and CRP correlate with higher risk of stroke, heart failure, and recurrence following ablation or cardioversion.
Risk scores integrating clinical data with genetic and biomarker information are under development, aiming to refine existing tools like CHA₂DS₂-VASc. These advances can guide decisions around anticoagulation, rhythm vs. rate control strategies, and timing of invasive procedures. As multi-omics data become more accessible, stratification models will become more robust, supporting individualized AFib care and improved outcomes.